Cardiovascular Disorders Drug Development Market volume, revenue, product price, top players, market share and growth rate

Latest industry research report on: Cardiovascular Disorders Drug Development Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts

Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic plaques building up within blood vessels. As atheroma develops its causes stenosis of the blood vessels which can restrict blood flow to the body, brain or heart depending on its locale. It is also possible for the fibrous cap of the plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally which can completely occlude blood flow.

The treatments of CVD typically focus on prevention by controlling the risk factors of CVD. As such, the treatments usually fall within three categories: Anti-hypertensives aim to lower blood pressure; anti-dyslipidemia drugs aim to alter lipid levels to an acceptable range; and anti-thrombotic drugs aim to either prevent thrombus forming or work to mitigate the damage of a current thrombi, they do this by either interrupting the coagulation cascade or inhibiting platelet aggregation, both of which inhibit blood from clotting.

Download Sample copy of this Report at :http://www.marketresearchreports.biz/sample/sample/1049123

There are over 1,200 pipeline products within the CVD therapy area. Over 50% of these products are small molecules however there is also diversification with regards to molecule types within the pipeline. In addition, the molecular targets in the pipeline are considerably diverse with a high frequency of products acting on targets related to lipid metabolism and those which act on elements of the coagulation cascade.

Among those pipeline drugs expected for imminent release to market there is a mixture of first-in-class products, typically anti-dyslipidemia drugs aiming to provide alternatives to statin therapy, and drugs belonging to currently popular classes such as PCSK9 inhibitors and direct factor Xa inhibitors.

The report provides comprehensive information on the pipeline development landscape for Hypertension, Dyslipidemia, Venous thromboembolism and Heart failure, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

Which companies are the most active within the pipeline for CVD.

Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication.

To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies.

What are the most important R&D milestones and data publications to have happened in this disease area.

Reasons to buy

Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

GBI Research Report Guidance 2

Executive Summary 3

Table of Contents 4

List of Tables 6

List of Figures 15

Introduction 18

Cardiovascular Disorders Report Coverage 18

Hypertension Overview 18

Dyslipidemia Overview 18

Thromboembolism Overview 18

Heart Failure Overview 18

Therapeutics Development 20

Hypertension 20

Dyslipidemia 22

Thromboembolism 24

Heart Failure 26

Therapeutics under Development by Companies 31

Hypertension 31

Dyslipidemia 35

Thromboembolism 39

Heart Failure 40

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact Us

State Tower

90 State Street, Suite 700

Albany, NY 12207

United States

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

Email: sales@marketresearchreports.biz

This release was published on openPR.